Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IG vs ANIK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANIK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

ANIK Overall Winner 6-Pillar Tally: IG 1 – 5 ANIK Matrix Metrics: IG 1 – 9 ANIK

As of Nov 16, 2026, Anika Therapeutics Inc (ANIK) is the stronger overall head-to-head candidate over Principal Investment Grade Corporate Active ETF (IG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IG carries a Unified Composite Score of 45.4/100 (HOLD) at $19.61 (N/M Forward P/E, N/A operating margin), whereas ANIK carries 48.5/100 (HOLD) at $12.92 (12.9x Forward P/E, -0.1% operating margin).

  • Technical & Structure Timing Caution: IG is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 39.4); meanwhile ANIK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IG vs ANIK
IG NYSE Arca
Principal Investment Grade Corporate Active ETF
Institutional Equity
$19.61
-0.02% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.18β · 7% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.8%) with fading momentum, RSI 39
RSI-14: 39.4 · SMA20: $19.78 · SMA50: $19.77
ANIK NASDAQ Head-to-Head Winner
Anika Therapeutics Inc
Surgical & Medical Instruments & Apparatus
$12.92
-3.58% 1D
Market Cap $179.5M
TTM Revenue $123M
Forward P/E 12.9x
Beta / 30D Vol 0.91β · 98% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 22
RSI-14: 22.3 · SMA20: $18.29 · SMA50: $19.50

6-Pillar Scorecard Institutional Category Breakdown (IG 1 – 5 ANIK)

Columns: Metric · IG · ANIK
1. Valuation Multiples ANIK
Forward P/E N/M 12.9x
Trailing P/E N/M 13.4x
PEG Ratio N/M 1.34x
EV / Revenue N/M 1.3x
2. Growth & Scale ANIK
Revenue Growth (YoY) N/A +10.0%
Earnings Growth (YoY) N/A -50.5%
TTM Revenue (USD) N/A $123M
Market Cap N/A $179.5M
3. Profitability & Quality ANIK
Gross Margin N/A 63.4%
Operating Margin N/A -0.1%
Net Profit Margin N/A -1.4%
Return on Equity (ROE) N/A -0.2%
4. Balance Sheet & Cash Flow ANIK
Cash Generation (TTM) N/A $2.3M
Cash Flow Margin N/A 1.9%
Net Cash / Leverage N/A ROE $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 39.5% (6th %ile)
Put/Call OI Skew N/A 1.43x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ANIK
OpEx & R&D Intensity N/A 63.5% of Rev ($78M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IG (1) vs ANIK (9)
Institutional Metric IG ANIK Criterion Row Edge
Market Capitalization
Scale
N/A $179.5M Larger Scale ANIK
Trailing P/E Ratio
Valuation
N/M 13.4x Lower Multiple ANIK
Forward P/E Ratio
Valuation
N/M 12.9x Lower Multiple ANIK
Revenue Growth (YoY)
Growth
N/A +10.0% Higher Growth ANIK
Operating Margin (TTM)
Profitability
N/A -0.1% Higher Margin ANIK
Net Profit Margin
Profitability
N/A -1.4% Higher Margin ANIK
Return on Equity (ROE)
Capital Efficiency
N/A -0.2% Higher ROE ANIK
52-Week Range Position
Momentum
14% ($19–$21) 28% ($9–$23) Stronger Trend ANIK
Beta / 30D Volatility
Risk Regime
0.18β · 7% Vol 0.91β · 98% Vol Lower Realized Risk IG
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite ANIK
Trailing 12M Revenue (USD)
Operating Scale
N/A $123M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 63.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.34x PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $2.3M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IG +34.73 pp
IG: -0.61% · ANIK: -35.34%
3M Horizon IG +37.32 pp
IG: -2.78% · ANIK: -40.1%
6M Horizon IG +9.59 pp
IG: -3.99% · ANIK: -13.58%
1Y Horizon ANIK +34.06 pp
IG: -6.14% · ANIK: +27.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IG vs ANIK. Trailing 12-month operating profitability (IG N/A vs ANIK -0.1%) and valuation multiples (IG N/M vs ANIK 12.9x Forward P/E) are benchmarked directly in Pillar 4 below.

IG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ANIK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$123M
Gross Margin63.4%
Op. Margin-0.1%
ROE / Fwd P/E-0.2% · 12.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANIK BREAKDOWN
67d in phase · OBV DISTRIBUTION
Current IV 39.5%
IV Percentile 6th %ile
Put/Call OI Skew 1.43x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANIK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANIK Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $179.5M market capitalization and -0.1% operating margin.
OpEx & R&D Reinvestment 63.5% of Rev ($78M)
90D Engineering Disclosures 0 Published

Investor FAQ IG vs ANIK Key Questions & Quantitative Answers

As of Nov 16, 2026, Anika Therapeutics Inc (ANIK) is the stronger overall head-to-head candidate over Principal Investment Grade Corporate Active ETF (IG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IG carries a Unified Composite Score of 45.4/100 (HOLD) at $19.61 (N/M Forward P/E, N/A operating margin), whereas ANIK carries 48.5/100 (HOLD) at $12.92 (12.9x Forward P/E, -0.1% operating margin). Technical & Structure Timing Caution: IG is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 39.4); meanwhile ANIK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANIK leads the Growth & Scale pillar: IG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ANIK at +10.0% YoY revenue growth and -50.5% YoY earnings growth on $123M TTM revenue (63.4% gross margin, -0.1% operating margin). On trailing 12-month operating scale, IG generates N/A in USD-normalized revenue versus $123M for ANIK. In operating R&D and SG&A reinvestment, IG deploys N/A (0 90-day corporate R&D disclosures) versus 63.5% of Rev ($78M) (0 disclosures) for ANIK.

ANIK screens cheaper on headline valuation multiples. IG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ANIK trades at 12.9x Forward P/E, 13.4x Trailing P/E, 1.34x PEG, and 1.3x EV/Revenue (1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IG (N/A ROE) versus ANIK (-0.2% ROE) capital efficiency.

In options market volatility and institutional positioning, IG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 7% Vol realized risk). By comparison, ANIK carries 39.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 1.43x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.91β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.